Get the Stockscreener App
0.00
100.00%
-2.65
After Hours:
2.65
2.65
+
Repare Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
See More
Previous Close:
$2.65
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$114.24M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
0.00
EPS:
-2.23
Net Cash Flow:
$-129.10M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$2.66
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
(857) 412-7018
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Compare RPTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
0.00 | 114.24M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
Repare Therapeutics announces shareholder meeting for acquisition approval - MSN
RPTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Repare Therapeutics Inc. stock benefit from infrastructure spendingCEO Change & Expert Curated Trade Ideas - mfd.ru
Is Repare Therapeutics Inc forming a bullish divergenceForecast Cut & Low Volatility Stock Recommendations - baoquankhu1.vn
Will Repare Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Spike Watch & Risk Controlled Swing Trade Alerts - mfd.ru
[15-12G] Repare Therapeutics Inc. SEC Filing - Stock Titan
How Repare Therapeutics Inc. stock reacts to oil prices2025 Price Targets & Verified Technical Trade Signals - mfd.ru
Is Repare Therapeutics Inc. stock heavily shortedMarket Risk Summary & AI Driven Price Forecasts - mfd.ru
Why Repare Therapeutics Inc. stock could outperform in 2025July 2025 Market Mood & Safe Capital Growth Tips - mfd.ru
Is Repare Therapeutics Inc. stock a smart buy before Fed meetingEarnings Beat & Community Shared Stock Ideas - mfd.ru
Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026 - marketscreener.com
Gilead’s Growing Oncology Role Reshapes The Investment Case For GILD - Sahm
Published on: 2026-02-02 06:19:02 - baoquankhu1.vn
Shay Capital LLC's Strategic Acquisition of Repare Therapeutics Inc Shares - GuruFocus
Repare Therapeutics completes acquisition and goes private - The Globe and Mail
Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Up 125.3% in January - MarketBeat
Repare Announces Completion of Acquisition by XenoTherapeutics - citybiz
Repare Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView
RPTX Technical Analysis & Stock Price Forecast - Intellectia AI
Repare Shareholders Approve Acquisition by XenoTherapeutics - citybiz
Repare Shareholders approve acquisition by XenoTherapeutics - Medical Buyer
Repare Therapeutics (RPTX) Shareholders Approve Acquisition by X - GuruFocus
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. - Investing News Network
Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics - TipRanks
99.76% of Repare voters back takeover by nonprofit XenoTherapeutics - Stock Titan
Bank Watch: Is Repare Therapeutics Inc stock heavily shorted2025 Support & Resistance & Reliable Intraday Trade Plans - baoquankhu1.vn
Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Update - MarketBeat
Update Report: Is Repare Therapeutics Inc stock heavily shorted2025 Market Trends & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4%Here's Why - MarketBeat
Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4% – Here’s Why - Defense World
Levels Update: Is Repare Therapeutics Inc. stock a top pick in earnings season2025 Sector Review & Daily Stock Trend Watchlist - Bộ Nội Vụ
Aug Opening: Will Repare Therapeutics Inc stock attract ESG investorsMarket Sentiment Summary & AI Driven Stock Price Forecasts - Bộ Nội Vụ
Insider Trends: Why Repare Therapeutics Inc. stock is in analyst buy zonePortfolio Update Report & Capital Efficient Trading Techniques - Bộ Nội Vụ
Published on: 2026-01-13 02:16:07 - baoquankhu1.vn
What catalysts could drive Repare Therapeutics Inc. stock higherTrade Exit Summary & Smart Investment Allocation Tips - Улправда
Oklahoma City NewsThe OklahomanRepare Therapeutics Inc.Common Shares (Nasdaq:RPTX) Stock Quote - FinancialContent
Is Repare Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Review & Risk Managed Trade Strategies - Улправда
Can Repare Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Weekly Recap & Weekly Top Stock Performers List - Улправда
Will Repare Therapeutics Inc. stock benefit from commodity prices2025 Big Picture & Momentum Based Trading Signals - ulpravda.ru
Repare Therapeutics sells RP-3467 cancer program assets to Gilead for up to $30 million - MSN
Can Repare Therapeutics Inc. stock double in next 5 yearsVolatility Adjusted Trading & Learn to Trade with Real-Time Feedback - Улправда
Repare Therapeutics Inc.Common Shares (NQ: RPTX - FinancialContent
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
Repare Therapeutics Announces Gilead Acquisition of RP-3467 for Up to $30 Million - citybiz
PYXS,RPTX Dividends - Finviz
Repare Therapeutics announces CSO resignation and transition plan - MSN
Repare Therapeutics Sells RP-3467 Program to Gilead - The Globe and Mail
Aug Drivers: How buybacks impact Repare Therapeutics Inc stock valueMarket Movement Recap & Weekly High Return Stock Forecasts - moha.gov.vn
Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact - Investing.com Nigeria
Repare Therapeutics Signs Asset Purchase Agreement With Gilead Sciences - TradingView — Track All Markets
Repare Sells Key Oncology Asset to Gilead, Lifts Expected Xeno Deal Payout - TipRanks
Repare Therapeutics Inc Stock (RPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):